Abstract 922P
Background
Genomic instability is an hallmark of cancer that has been associated to immune evasion, cancer progression and multidrug resistance. MOSCATO (NCT) was a prospective clinical trial evaluating the clinical benefit of high-throughput genomic analyses in patients with advanced solid tumors. In this study we investigated a genomic instability score based on somatic copy number alterations as determined by Single Nucleotide Polymorphism (SNP) array as a biomarker for head and neck cancer patients.
Methods
Extracted DNA from fresh frozen tumor was analyzed using high-resolution Affymetrix Cytoscan® HD array whereas extracted DNA from FFPE samples was analyzed using the Affymetrix Oncoscan® CNV assay. The absolute copy-number (ACN) profile was generated by ASCAT v3.1 through EaCoN v0.3.6 (https://github.com/gustaveroussy/EaCoN, PMID 36669143) on R v4.1.1 and then the genomic instability score (GIS) was estimated as the sum of the segment length multiplied by the absolute difference between segment copy number and the ASCAT estimated sample ploidy. This sum is reported to the reference genome length. In parallel, somatic mutation were assessed with a NGS panel covering including at least 75 critical oncogenes and tumor suppressor genes.
Results
SNP array data were available for 58 patients out of the 111 with head and neck cancers. 38 were men, 34 had squamous histology (SCC), 13 cystadenocarcinoma (ACC) and 11 other types (adenocarcinoma, mucinous carcinoma). Patients with SCC had higher GIS (median 0.53 for SCC vs 0.05 for ACC and 0.40 for others). At genomic level, the presence of TP53 (p < 0.001) and ATM (p 0.056) were associated with higher GIS. This was confirmed also after adjusting for histology. Conversely, GIS score was not associated with age. Patients with SCC that were positive for HPV (n=11) had lower GIS respect to HPV negatives (n=14, 0.24 vs 0.85, p 0.05) Higher GIS score was associated with decreased OS after adjusting for histology (HR 1.87, 95% CI 1.31 - 2.65, p < 0.001).
Conclusions
Genomic instability score based on SNP array copy number alterations profile is associated with worse prognosis in patients with carcinoma of the head and neck. Higher GIS score is found in squamous cell carcinomas and is associated with mutations in genes involved in cell cycle control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03